Sectors

4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Pfizer Ventures and Chiesi Ventures returned to back inherited disease therapy developer 4D Molecular Therapeutics, which filed to go public in September.

The carmaker has followed up a $100m investment two years ago with a pledge to provide up to $200m for the solid-state battery developer.

The Roche, Novartis and Kraft Group-backed, protein degradation-focused drug developer received $150m in series B funding and $20m in venture debt.

SK China, Xiaomi and Lenovo were among the investors as BYD's electric vehicle chip spinoff added $113m to the $265m it announced last month.

Continental Grain invested in a series D round that boosted the RNA technology provider's overall funding to $214m as it allocates more resources to vaccine work.

Returning investors Axel Springer and Purplebricks combined to invest $45.2m in the online real estate brokerage that will fund hiring and product development.

The move came after the digital health technology provider, which has a raft of corporate investors, reportedly failed to raise a nine-figure round last year.

With campuses shuttered in the pandemic, society needs to find solutions quickly to continue education and avoid a lost generation of skilled workers.

Next47 and M12 took part in Wandelbots' latest round, which came as it publicly launched its robotics training software tool.

Sector analysis: Health & life sciences